-
1
-
-
0034052301
-
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome
-
Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000; 29:296–304.
-
(2000)
Semin Arthritis Rheum
, vol.29
, pp. 296-304
-
-
Skopouli, F.N.1
Dafni, U.2
Ioannidis, J.P.3
Moutsopoulos, H.M.4
-
2
-
-
84863218864
-
Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry
-
Malladi AS, Sack KE, Shiboski SC et al. Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64:911–8.
-
(2012)
Arthritis Care Res (Hoboken)
, vol.64
, pp. 911-918
-
-
Malladi, A.S.1
Sack, K.E.2
Shiboski, S.C.3
-
3
-
-
84863497528
-
Topical and systemic medications for the treatment of primary Sjogren's syndrome
-
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjogren's syndrome. Nat Rev Rheumatol 2012; 8:399–411.
-
(2012)
Nat Rev Rheumatol
, vol.8
, pp. 399-411
-
-
Ramos-Casals, M.1
Brito-Zerón, P.2
Sisó-Almirall, A.3
Bosch, X.4
Tzioufas, A.G.5
-
4
-
-
0344585384
-
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice
-
Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171:6173–7.
-
(2003)
J Immunol
, vol.171
, pp. 6173-6177
-
-
Nakae, S.1
Nambu, A.2
Sudo, K.3
Iwakura, Y.4
-
5
-
-
66849099394
-
Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism
-
Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 2009; 7:e003.
-
(2009)
Nucl Recept Signal
, vol.7
-
-
Jetten, A.M.1
-
6
-
-
84919665375
-
A crucial role of RORγt in the development of spontaneous sialadenitis-like Sjögren's syndrome
-
Iizuka M, Tsuboi H, Matsuo N et al. A crucial role of RORγt in the development of spontaneous sialadenitis-like Sjögren's syndrome. J Immunol 2015; 194:56–67.
-
(2015)
J Immunol
, vol.194
, pp. 56-67
-
-
Iizuka, M.1
Tsuboi, H.2
Matsuo, N.3
-
7
-
-
37849048599
-
T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ
-
Yang XO, Pappu BP, Nurieva R et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 2008; 28:29–39.
-
(2008)
Immunity
, vol.28
, pp. 29-39
-
-
Yang, X.O.1
Pappu, B.P.2
Nurieva, R.3
-
9
-
-
39449101603
-
Transcriptional regulation of Th17 cell differentiation
-
Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007; 19:409–17.
-
(2007)
Semin Immunol
, vol.19
, pp. 409-417
-
-
Ivanov, I.I.1
Zhou, L.2
Littman, D.R.3
-
10
-
-
44049104564
-
The differentiation of human TH-17 cells requires transforming growth factor-b and induction of the nuclear receptor RORγt
-
Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor-b and induction of the nuclear receptor RORγt. Nat Immunol 2008; 9:641–9.
-
(2008)
Nat Immunol
, vol.9
, pp. 641-649
-
-
Manel, N.1
Unutmaz, D.2
Littman, D.R.3
-
11
-
-
84923870123
-
ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes
-
Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology 2015; 156:869–81.
-
(2015)
Endocrinology
, vol.156
, pp. 869-881
-
-
Solt, L.A.1
Banerjee, S.2
Campbell, S.3
Kamenecka, T.M.4
Burris, T.P.5
-
12
-
-
84896287211
-
Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor γ is therapeutic in the collagen-induced arthritis experimental model
-
Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor γ is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol 2014; 66:579–88.
-
(2014)
Arthritis Rheumatol
, vol.66
, pp. 579-588
-
-
Chang, M.R.1
Lyda, B.2
Kamenecka, T.M.3
Griffin, P.R.4
-
13
-
-
77958150989
-
Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjögren's syndrome-like sialoadenitis
-
Iizuka M, Wakamatsu E, Tsuboi H et al. Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjögren's syndrome-like sialoadenitis. J Autoimmun 2010; 35:383–9.
-
(2010)
J Autoimmun
, vol.35
, pp. 383-389
-
-
Iizuka, M.1
Wakamatsu, E.2
Tsuboi, H.3
-
14
-
-
33947602423
-
Regulation of salivary gland function by autonomic nerves
-
Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosci 2007; 133:3–18.
-
(2007)
Auton Neurosci
, vol.133
, pp. 3-18
-
-
Proctor, G.B.1
Carpenter, G.H.2
-
15
-
-
14144251323
-
Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome
-
Naito Y, Matsumoto I, Wakamatsu E et al. Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome. Ann Rheum Dis 2005; 64:510–1.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 510-511
-
-
Naito, Y.1
Matsumoto, I.2
Wakamatsu, E.3
-
16
-
-
0035145180
-
Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren's syndrome
-
Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren's syndrome. Invest Ophthalmol Vis Sci 2001; 42:321–7.
-
(2001)
Invest Ophthalmol Vis Sci
, vol.42
, pp. 321-327
-
-
Bacman, S.1
Berra, A.2
Sterin-Borda, L.3
Borda, E.4
-
17
-
-
37749048646
-
High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile onset Sjögren syndrome
-
Nakamura Y, Wakamatsu E, Matsumoto I et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile onset Sjögren syndrome. Ann Rheum Dis 2008; 67:136–7.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 136-137
-
-
Nakamura, Y.1
Wakamatsu, E.2
Matsumoto, I.3
-
18
-
-
77956496706
-
New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome
-
Tsuboi H, Matsumoto I, Wakamatsu E et al. New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. Clin Exp Immunol 2010; 162:53–61.
-
(2010)
Clin Exp Immunol
, vol.162
, pp. 53-61
-
-
Tsuboi, H.1
Matsumoto, I.2
Wakamatsu, E.3
-
19
-
-
31144439287
-
Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjögren's syndrome
-
Naito Y, Matsumoto I, Wakamatsu E et al. Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjögren's syndrome. Ann Rheum Dis 2006; 65:269–71.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 269-271
-
-
Naito, Y.1
Matsumoto, I.2
Wakamatsu, E.3
-
20
-
-
84877773390
-
The crucial roles of IFN-γ in the development of M3 muscarinic acetylcholine receptor induced Sjögren's syndrome-like sialadenitis
-
Iizuka M, Tsuboi H, Matsuo N et al. The crucial roles of IFN-γ in the development of M3 muscarinic acetylcholine receptor induced Sjögren's syndrome-like sialadenitis. Mod Rheumatol 2013; 23:614–6.
-
(2013)
Mod Rheumatol
, vol.23
, pp. 614-616
-
-
Iizuka, M.1
Tsuboi, H.2
Matsuo, N.3
-
21
-
-
84983458530
-
M3 muscarinic acetylcholine receptor reactive IL-17 producing T cells promotes development of Sjögren's syndrome like sialadenitis
-
Iizuka M, Tsuboi H, Asashima H et al. M3 muscarinic acetylcholine receptor reactive IL-17 producing T cells promotes development of Sjögren's syndrome like sialadenitis. Mod Rheumatol 2015; 25:158–60.
-
(2015)
Mod Rheumatol
, vol.25
, pp. 158-160
-
-
Iizuka, M.1
Tsuboi, H.2
Asashima, H.3
-
22
-
-
0034662903
-
Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype
-
Matsui M, Motomura D, Karasawa H et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A 2000; 97:9579–84.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 9579-9584
-
-
Matsui, M.1
Motomura, D.2
Karasawa, H.3
-
23
-
-
78649539346
-
IFN-g and IL-12 synergize to convert in vivo generated Th17 into Th1 Th17 cells
-
Lexberg MH, Taubner A, Albrecht I et al. IFN-g and IL-12 synergize to convert in vivo generated Th17 into Th1 Th17 cells. Eur J Immunol 2010; 40:3017–27.
-
(2010)
Eur J Immunol
, vol.40
, pp. 3017-3027
-
-
Lexberg, M.H.1
Taubner, A.2
Albrecht, I.3
-
24
-
-
58149251898
-
Late developmental plasticity in the T helper 17 linage
-
Lee YK, Turner H, Maynard CL et al. Late developmental plasticity in the T helper 17 linage. Immunity 2009; 30:92–107.
-
(2009)
Immunity
, vol.30
, pp. 92-107
-
-
Lee, Y.K.1
Turner, H.2
Maynard, C.L.3
-
25
-
-
58149216715
-
Th memory for interleukin-17 expression is stable in vivo
-
Lexberg MH, Taubner A, Förster A et al. Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol 2008; 38:2654–64.
-
(2008)
Eur J Immunol
, vol.38
, pp. 2654-2664
-
-
Lexberg, M.H.1
Taubner, A.2
Förster, A.3
-
26
-
-
84876907317
-
Activity of T-helper cells on patients with primary Sjögren's syndrome
-
Sudzius G, Mieliauskaite D, Butrimiene I, Siaurys A, Mackiewicz Z, Dumalakiene I. Activity of T-helper cells on patients with primary Sjögren's syndrome. In Vivo 2013; 27:263–8.
-
(2013)
In Vivo
, vol.27
, pp. 263-268
-
-
Sudzius, G.1
Mieliauskaite, D.2
Butrimiene, I.3
Siaurys, A.4
Mackiewicz, Z.5
Dumalakiene, I.6
-
27
-
-
84876777999
-
ILC1 populations join the border patrol
-
Maloy KJ, Uhlig HH. ILC1 populations join the border patrol. Immunity 2013; 38:630–2.
-
(2013)
Immunity
, vol.38
, pp. 630-632
-
-
Maloy, K.J.1
Uhlig, H.H.2
-
28
-
-
84898640432
-
Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages
-
Klose CS, Flach M, Möhle L et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014; 157:340–56.
-
(2014)
Cell
, vol.157
, pp. 340-356
-
-
Klose, C.S.1
Flach, M.2
Möhle, L.3
-
29
-
-
84876780238
-
Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells
-
Fuchs A, Vermi W, Lee JS et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. Immunity 2013; 38:769–81.
-
(2013)
Immunity
, vol.38
, pp. 769-781
-
-
Fuchs, A.1
Vermi, W.2
Lee, J.S.3
-
31
-
-
84924370171
-
Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with Orencia trial toward Sjögren's syndrome endocrinopathy (ROSE) trial-an open-label, one-year, prospective study –interim analysis of 32 patients for 24 weeks
-
Tsuboi H, Matsumoto I, Hagiwara S et al. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with Orencia trial toward Sjögren's syndrome endocrinopathy (ROSE) trial-an open-label, one-year, prospective study –interim analysis of 32 patients for 24 weeks. Mod Rheumatol 2015; 25:187–93.
-
(2015)
Mod Rheumatol
, vol.25
, pp. 187-193
-
-
Tsuboi, H.1
Matsumoto, I.2
Hagiwara, S.3
-
32
-
-
54349116244
-
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomized, double-blind, placebo-controlled pilot study
-
Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomized, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541–4.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1541-1544
-
-
Dass, S.1
Bowman, S.J.2
Vital, E.M.3
-
33
-
-
84877611272
-
Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
-
Gottenberg JE, Cinquetti G, Larroche C et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72:1026–31.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1026-1031
-
-
Gottenberg, J.E.1
Cinquetti, G.2
Larroche, C.3
-
34
-
-
84938686604
-
Efficacy and safety of rituximab in systemic lupus erythematosus and Sjogren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases
-
Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. Efficacy and safety of rituximab in systemic lupus erythematosus and Sjogren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol 2015; 23:244–50.
-
(2015)
J Clin Rheumatol
, vol.23
, pp. 244-250
-
-
Jiang, B.1
Li, T.2
Guo, L.3
Shen, H.4
Ye, S.5
Chen, S.6
-
35
-
-
84894243056
-
Treatment of primary Sjögren syndrome with rituximab: a randomized trial
-
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160:233–42.
-
(2014)
Ann Intern Med
, vol.160
, pp. 233-242
-
-
Devauchelle-Pensec, V.1
Mariette, X.2
Jousse-Joulin, S.3
-
37
-
-
0023976470
-
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
-
Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7:711–7.
-
(1988)
EMBO J
, vol.7
, pp. 711-717
-
-
Einfeld, D.A.1
Brown, J.P.2
Valentine, M.A.3
Clark, E.A.4
Ledbetter, J.A.5
-
38
-
-
0024410224
-
Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C
-
Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989; 264:11282–7.
-
(1989)
J Biol Chem
, vol.264
, pp. 11282-11287
-
-
Valentine, M.A.1
Meier, K.E.2
Rossie, S.3
Clark, E.A.4
|